Read More Pharma Industry News Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan. bySrinathMay 30, 2026